Sanofi sees faster profit growth on Dupixent, flu vaccine demandBusiness, R&D, TherapeuticsFrench drugmaker Sanofi on Friday forecast faster earnings growth this year on strong demand for its bestselling drug Dupixent and for its flu vaccines, spurring a rise in its battered share price. Read more October 28, 2022/by Reuters Health https://www.pharmalive.com/wp-content/uploads/2022/06/ReutersSanofi6-29-2022.jpg 800 1200 Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Reuters Health2022-10-28 03:27:372022-10-28 10:30:28Sanofi sees faster profit growth on Dupixent, flu vaccine demand
